



EPSD: a well-annotated data resource of protein phosphorylation sites in eukaryotes

Shaofeng Lin[†], Chenwei Wang[†], Jiaqi Zhou, Ying Shi, Chen Ruan, Yiran Tu, Lan Yao, Di Peng and Yu Xue

Corresponding author: Yu Xue, Key Laboratory of Molecular Biophysics of Ministry of Education, Hubei Bioinformatics and Molecular Imaging Key Laboratory, Center for Artificial Intelligence Biology, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China. Tel.: +86-27-87793903; Fax: +86-27-87793172; E-mail: xueyu@hust.edu.cn

[†]These two authors contributed equally to this work.

Abstract

As an important post-translational modification (PTM), protein phosphorylation is involved in the regulation of almost all of biological processes in eukaryotes. Due to the rapid progress in mass spectrometry-based phosphoproteomics, a large number of phosphorylation sites (p-sites) have been characterized but remain to be curated. Here, we briefly summarized the current progresses in the development of data resources for the collection, curation, integration and annotation of p-sites in eukaryotic proteins. Also, we designed the eukaryotic phosphorylation site database (EPSD), which contained 1 616 804 experimentally identified p-sites in 209 326 phosphoproteins from 68 eukaryotic species. In EPSD, we not only collected 1 451 629 newly identified p-sites from high-throughput (HTP) phosphoproteomic studies, but also integrated known p-sites from 13 additional databases. Moreover, we carefully annotated the phosphoproteins and p-sites of eight model organisms by integrating the knowledge from 100 additional resources that covered 15 aspects, including phosphorylation regulator, genetic variation and mutation, functional annotation, structural annotation, physicochemical property, functional domain, disease-associated information, protein-protein interaction, drug-target relation, orthologous information, biological pathway, transcriptional regulator, mRNA expression, protein expression/proteomics and subcellular localization. We anticipate that the EPSD can serve as a useful resource for further analysis of eukaryotic phosphorylation. With a data volume of 14.1 GB, EPSD is free for all users at <http://epsd.biocuckoo.cn/>.

Key words: phosphorylation; phosphorylation site; post-translational modification; phosphoproteomics; PLK1

Shaofeng Lin is a PhD student at Huazhong University of Science and Technology. His major research interest is focused on the integration of PTM data. He developed a database named dbPAF for known protein phosphorylation sites in human, animals and fungi. He was a major developer of iUUCD 2.0, a database of ubiquitin and ubiquitin-like conjugations.

Chenwei Wang is a PhD student at Huazhong University of Science and Technology. He mainly focuses on the development of new algorithms to predict functional PTM events from multi-omic data.

Jiaqi Zhou is a PhD student at Huazhong University of Science and Technology. She was a major developer of iUUCD 2.0. Her major research interest is the development of PTM-related data resources.

Ying Shi is a master student at Huazhong University of Science and Technology. She mainly focuses on the collection and integration of known phosphorylation sites in prokaryotes.

Chen Ruan is a PhD student at Huazhong University of Science and Technology. He mainly focuses on the experimental identification of potentially important protein kinases involved in regulating autophagy.

Yiran Tu is a master student at Huazhong University of Science and Technology. He is working on the experimental identification of PTM regulators involved in autophagy.

Lan Yao is a master student at Huazhong University of Science and Technology. She focuses on the experimental identification of phosphorylated substrates in yeast autophagy.

Di Peng is a postdoc scientist at Huazhong University of Science and Technology. His major research interests are focused on the experimental discovery of new PTM regulators, substrates and sites, based on computational predictions. He was a major developer of iEKP2.0, a database of protein phosphorylation regulators in eukaryotes.

Yu Xue is a professor at Huazhong University of Science and Technology. He has started to work in the field of PTM Bioinformatics since 2004. He is interested in using both computational and experimental approaches to exploit how functional PTM events can be precisely orchestrated to regulate various biological processes, such as autophagy, circadian and cell fate determination.

Submitted: 21 October 2019; **Received (in revised form):** 25 November 2019

Introduction

Protein phosphorylation is one of the most indispensable and well-characterized posttranslational modifications (PTMs). It mainly occurs at specific serine, threonine and tyrosine residues of phosphoproteins, and participates in the regulation of almost all of biological processes and pathways in eukaryotes [1–12]. The regulation of phosphorylation events is highly dynamic and accurate *in vivo*, whereas aberrance in the phosphorylation system is closely associated with a variety of human diseases, such as cancer, neurodegenerative disease and diabetes [13–17]. Thus, the identification and functional analyses of phosphorylation sites (p-sites) in phosphoproteins provide the foundation for understanding the molecular mechanisms and regulatory roles of protein phosphorylation in eukaryotes.

Advances in chemical labeling strategies, phosphopeptide enrichment techniques and liquid chromatography-tandem mass spectrometry have resulted in rapid progress in high-throughput (HTP) phosphoproteomics, which enables thousands of p-sites to be quantitatively identified in a single run. For example, Humphrey *et al.* developed a sophisticated phosphoproteomics platform, EasyPhos, to generate time-course maps of insulin signaling dynamics from the large-scale quantification of 31 605 phosphopeptides in mouse liver tissues [1]. Additionally, Liu *et al.* used EasyPhos to quantify approximately 50 000 p-sites from five mouse brain regions and systematically investigated the *in vivo* signaling of the kappa opioid receptor, an important member of the G protein-coupled receptor superfamily [2]. In addition, using quantitative label-free technology, Drake *et al.* identified 8348 phosphopeptides from 27 samples of treatment-naive prostate cancer and metastatic castration-resistant prostate cancer patients and prioritized potentially therapeutic targets in a patient-specific manner [17]. Although many experimental studies have been conducted, the collection, curation, integration and annotation of the large number of p-sites remain to be performed.

In this manuscript, we first reviewed the mainstream p-site databases that were devoted to generate useful resources for academic community, including Phospho.ELM/PhosphoBase [3–5, 18], PhosphoSitePlus [6, 7], dbPTM [8, 9], Phospho3D [19, 20], PhosphoPOINT [21], SysPTM [22, 23], PhosphoNET [24], iPTM-net [10, 25], PHOSIDA [26, 27], PhosphoPep [28, 29], LymphOS [30, 31], PlantsP [32, 33], PhosPhAt [34, 35], P³DB [36, 37], MPPD [38, 39], FPD [40], PTMfunc [41], UniProt [42], HPRD [43] and BioGRID/PhosphoGRID [44, 45] (Supplementary Table S1). Previously, we also designed two databases, dbPPT [11] and dbPAF [12], which contained 82 175 p-sites in 31 012 proteins of 20 plants, and 483 001 p-sites in 54 148 substrates of human, 4 animals and 2 fungi, respectively. At that time, less annotation information was integrated. To provide a more comprehensive and integrative resource, here, we developed the eukaryotic p-site database (EPSD), by recuration all entries in the dbPPT [11] and dbPAF [12] databases, as well as an additional collection of 1 451 629 known p-sites that were newly identified from HTP studies of 68 eukaryotic species (Figure 1A). We also integrated known p-sites from 13 publicly available p-site databases (Supplementary Table S2). In addition, we provided rich annotations for phosphoproteins and p-sites of eight model organisms by integrating the knowledge from 100 additional resources that covered 15 aspects (Figure 1A, Supplementary Table S2). In total, EPSD contained 1 616 804 known p-sites, including 1 085 095 phosphoserine (pS), 394 648 phosphothreonine (pT) and 13 061 phosphotyrosine (pY) residues in 209 326 phosphoproteins. The EPSD will be continuously maintained and updated and can

serve as a useful resource for better understanding of eukaryotic phosphorylation.

Methods

Data collection was started from two previously constructed databases dbPPT [11] and dbPAF [12] which contained 565 176 experimentally identified p-sites of 85 160 phosphoproteins in 27 eukaryotes (Figure 1B). We carefully recurred each entry in the two databases to ensure the quality of the data. Then, we searched the PubMed database by using multiple keywords, including ‘phosphoproteome’, ‘phosphoproteomic’, ‘phosphoproteomics’, ‘large-scale phosphorylation’, ‘mass spectrometry phosphorylation’, ‘MS phosphorylation’, ‘phosphosite’ and ‘phospho-site’. We manually checked all retrieved manuscripts with corresponding supplemental materials and collected 2 509 188 phosphopeptides of 68 eukaryotic organisms from 722 HTP phosphoproteomic studies (Supplementary Table S3). For each study, the information regarding cell or tissue samples was also curated and reserved. In these studies, mass spectrometry spectral data sets were processed by a variety of tools, such as MaxQuant, to derive peptides and phosphopeptides, and a localization probability (LP) score was computationally assigned to each potential p-site in phosphopeptides that contained multiple serine, threonine or tyrosine residues, based on the cumulative binomial distribution [26]. LP scores range from 0 to 1, and a higher LP score represents a higher cumulative binomial probability for a site to be a real p-site [26]. However, LP scores of identified p-sites were only provided in 335 (46.40%) of the 722 studies (Supplementary Table S3). In this regard, as previously described [46], we classified the p-sites in original phosphopeptides of the 335 articles into four categories, including class I (>0.75), class II (≤0.75 and >0.5), class III (≤0.5 and ≥0.25) and class IV (<0.25), based on the precalculated LP scores directly taken from these papers. Thus, class I p-sites had a probability of at least 0.75 to be phosphorylated, whereas the cumulative binomial probability of all other phosphorylatable residues was ≤0.25 [26]. To ensure the consistency with the literature, all HTP p-sites were reserved and no additional filters were applied.

To pinpoint the exact positions of p-sites in the protein sequences, we downloaded the reference proteomes containing canonical (*.fasta files) and isoform sequences (*.additional.fasta files) of the 68 eukaryotes from the UniProt database (Release version 2018-02, [ftp://ftp.uniprot.org/](http://ftp.uniprot.org/)) [42]. For each species, we first mapped all phosphopeptides to canonical sequences, and nonmappable phosphopeptides were mapped to isoform sequences. From the HTP studies, we obtained 1 451 629 nonredundant p-sites of 195 351 proteins (Figure 1B).

In addition to the database and literature curation, we further integrated the known p-sites of 13 additional public databases, including Phospho.ELM [4, 5], PhosphoSitePlus [6, 7], dbPTM [8, 9], PhosphoPep [28, 29], PHOSIDA [26, 27], PhosPhAt [34, 35], P³DB [36, 37], SysPTM [22, 23], BioGRID [44, 45], MPPD [38, 39], FPD [40], HPRD [43] and UniProt [42] (Figure 1B, Supplementary Table S2). Other databases were not considered because the known p-sites were not downloadable (Supplementary Table S1). The details regarding the processing of each phosphorylation database were provided in the Supplementary methods. To avoid any bias, we remapped all p-sites in the dbPPT [11], dbPAF [12] and 13 additional databases to canonical sequences and then to isoform sequences for each organism. We merged this data set with our manually collected p-sites. After redundancy clearing, the EPSD




Figure 1. The procedure for the construction of the EPSPD database. First, we merged the dbPPT [11] and dbPAF [12] databases and carefully re-curated each entry. Next, we searched PubMed to collect newly identified p-sites. Then, known p-sites in 13 additional phosphorylation databases were integrated. In addition to basic annotations, we further annotated eight model organisms, including *H. sapiens*, *M. musculus*, *R. norvegicus*, *D. melanogaster*, *C. elegans*, *A. thaliana*, *S. pombe* and *S. cerevisiae*, by integrating the knowledge from 100 additional resources that covered 15 aspects, including phosphorylation regulator, genetic variation and mutation, functional annotation, structural annotation, physicochemical property, functional domain, disease-associated information, PPI, drug-target relation, orthologous information, biological pathway, transcriptional regulator, mRNA expression, protein expression/proteomics and subcellular localization. (B) The numbers of p-sites and phosphoproteins curated and integrated from dbPPT [11] and dbPAF [12], HTP studies and 13 additional databases.

contained 1 616 804 experimentally identified p-sites of 209 326 phosphoproteins in 68 eukaryotes (Figure 1B).

Results

A summary of the mainstream p-site databases for eukaryotic phosphorylation

The past two decades have witnessed a rapid increase of numbers of p-sites experimentally identified from eukaryotic proteins. The collection, curation, integration and annotation of these known p-sites not only generated useful resources for further experimental analyses, but also provided high-quality benchmark data sets for various computational purposes, including but not limited to the development of p-site predictors [47], the reconstruction of kinase-substrate networks [10, 25, 48, 49], the analysis of genetic variations and cancer mutations that change p-sites [15, 50], the evolutionary analysis of phosphorylation regulation [51, 52], the prioritization of potentially functional p-sites [41] and the identification of PTM crosstalks between phosphorylation and other types of PTMs [9]. Besides our previously developed dbPPT [11] and dbPAF [12],

there were at least 20 additional p-site databases, which were briefly reviewed in this manuscript (Supplementary Table S1).

PhosphoBase is the first phosphorylation database that was developed in 1998 [3]. Its 1.0 version only collected 398 p-sites of 156 proteins with from low-throughput (LTP) experiments, whereas its 2.0 release was considerably expanded to maintain 414 phosphoproteins with 1052 p-sites [3, 18]. In 2004, Diella et al. manually collected 1703 LTP p-sites of 556 protein substrates from the literature and developed a high-quality database named Phospho.ELM [4]. Later, PhosphoBase was merged into Phospho.ELM, and its 9.0 version also curated known p-sites from various HTP experiments, with a total number of 43 673 p-sites in 11 462 proteins [5]. As one of the best curated and most widely used p-site resources, PhosphoSitePlus was initially established in 2004 and currently contains 381 305 experimental p-sites from both LTP and HTP experiments [6, 7]. In 2006, Lee et al. developed dbPTM for multiple types of PTM sites [8], and known p-sites were directly taken from other databases including Phospho.ELM [4] and UniProt/Swiss-Prot [42]. The 2019 update of dbPTM further collected experimental PTM sites from HTP studies and covered >130 types of PTMs including phosphorylation [9]. dbPTM also provides predicted PTM sites

with high confidence [9]. Through database integration (DI), Phospho3D obtained 5387 p-sites that were mapped to protein 3D structures [19, 20]. By literature curation and DI, SysPTM 2.0 maintained known sites of ~50 types of PTMs, including 66 017 experimental p-sites in 18 333 proteins [22, 23]. Using a similar strategy, PhosphoNET integrated 22 698 phosphoproteins with 177 424 p-sites mainly in *Homo sapiens* [24]. More recently, through text mining and the integration of six public databases, Huang et al. constructed the iPTMnet database that contained 490 597 curated p-sites for PTM network discovery [10, 25].

It should be noted that the LTP p-sites only occupy a small proportion of totally reported p-sites. Due to rapid progresses in the MS-based phosphoproteomic profiling, a huge number of HTP p-sites has been detected and remained to be curated. In 2006, Olsen et al. developed the first MS-based p-site database, PHOSIDA, and its 2011 update contained 71 638 HTP p-sites of 18 262 proteins in five eukaryotes, including *H. sapiens*, *Mus musculus*, *Drosophila melanogaster*, *Caenorhabditis elegans* and *Saccharomyces cerevisiae* [26, 27]. Also, PhosphoPep [28, 29] and LymPHOS [30, 31] contained 81 335 and 15 566 MS-derived p-sites in four species and from primary human T cells, respectively. Beyond animals, the development of p-site databases for plants or fungi is also prevalent. In 2001, Gribskov et al. constructed the first plant-specific p-site database named PlantsP, which contained >300 HTP p-sites of about 200 plasma membrane proteins in *Arabidopsis thaliana* [32, 33]. Later, PhosPhAt was established with a greatly enhanced number of 28 760 MS-based *Arabidopsis* p-sites in its 4.0 version [34, 35]. As one of the most comprehensive p-site databases for plants, P³DB integrated 41 746 HTP p-sites of 14 299 proteins in nine plants [36, 37]. In particular, MPPD was designed as a well-organized resource by collecting 2650 HTP p-sites in roots of *Medicago truncatula* [38, 39], whereas FPD is the only fungus-specific database that contained 56 133 MS-derived p-sites for 11 fungi [40]. By compiling a large data set of multiple types of PTM sites from 11 eukaryotes, Beltrao et al. conducted a systematic prediction of potentially functional PTMs including phosphorylation, and related results were present in PTMfunc [41].

Besides professional databases that were mainly focused on eukaryotic phosphorylation or PTMs, a number of resources developed for more general purposes also curated and annotated p-sites. For example, as one of the most indispensable resource for protein annotations, UniProt also curated 18 466 phosphorylated proteins with 66 490 known p-sites [42]. HPRD, the best annotated resource for human proteins, collected 55 849 unique p-sites in 9541 human proteins release [43]. BioGRID, a widely used database of experimental protein-protein interactions (PPIs), also presented a subdatabase named PhosphoGRID to maintain 23 064 p-sites in 3264 budding yeast proteins [44, 45]. Undoubtedly, all these databases provided invaluable information for further analysis of eukaryotic phosphorylation.

A multilayer annotation of phosphoproteins and p-sites

In this study, we designed EPSD as a phosphoprotein-centered database. The EPSD ID (EP-) was automatically generated and assigned to each phosphoprotein as the primary accession, whereas the UniProt ID was used as the secondary accession for organizing the database. The basic annotations such as gene/protein names, GenBank Gene IDs, nucleotide and protein IDs, Ensembl gene, transcript and protein IDs, functional descriptions, protein sequences, nucleotide sequences of the coding region, keywords and gene ontology (GO) terms were taken from UniProt [42]. The annotations of major or minor

isoforms were referenced from the canonical or isoform sequences downloaded from UniProt [42], respectively.

By using 100 additional databases and computational tools that covered 15 aspects, we further annotated 97 871 phosphoproteins in eight model organisms, including *H. sapiens*, *M. musculus*, *Rattus norvegicus*, *D. melanogaster*, *C. elegans*, *A. thaliana*, *Schizosaccharomyces pombe* and *S. cerevisiae* (Figure 1A, Supplementary Table S2). The knowledge in these resources was carefully integrated, and the details regarding the processing of each resource are provided in the Supplementary methods. For example, to annotate upstream regulators of p-sites, we obtained experimentally identified kinase-substrate relations from PhosphoSitePlus [6, 7], Phospho.ELM [4, 5], PostMod [53], PSEA [54], PhosphoNetworks [55] and RegPhos [56], and we obtained known phosphatase-substrate relations in *H. sapiens* from HuPHO [57] and DEPOD [58]. We also used four tools, including GPS [59], NetworKIN [48], PKIS [60] and PhosphoPICK [61], to predict potential protein kinases for modifying the p-sites. In total, 12 databases or tools were adopted for the annotation of protein kinases or protein phosphatases that potentially modify or demodify known p-sites in the eight species (Supplementary methods). All data sets and annotations can be accessed at <http://epsd.biocuckoo.cn/Download.php>.

The data statistics of p-sites in the EPSD

In the EPSD, there are 1 616 804 experimentally identified p-sites of 209 326 nonredundant proteins integrated for 68 eukaryotes, including 18 animals, 7 protists, 24 plants and 19 fungi (Supplementary Table S4). The distribution of p-sites and unique proteins, as well as pS, pT and pY residues for each species, is illustrated in a heatmap (Figure 2A), whereas the detailed counts are shown in Supplementary Table S4.

For all p-sites, there were 1 085 095 (67.11%) pS, 394 648 (24.41%) pT and 137 061 (8.48%) pY residues. We analyzed the distribution of the numbers of p-sites in phosphoproteins, and the results showed that up to 152 577 proteins (72.89%) are multiply phosphorylated with ≥ 2 known p-sites, indicating that multisite phosphorylation is the predominant mechanism for the regulation of protein substrates (Figure 2B). In particular, 4457 (2.13%) proteins are heavily phosphorylated with ≥ 50 p-sites, indicating a highly complicated phosphorylation code in these proteins (Figure 2B). From the analysis of the disorder propensities of p-sites in eight species, we observed that only pY residues had a strong preference (74.01%) to locate in protein ordered regions (Figure 2C). Moreover, the distribution of numbers of human p-sites in different cells or tissues was counted, and we found that 167 459 (37.57%) of known p-sites were only detected in one cell/tissue sample (Figure 2D). Whether these sites were cell- or tissue-specific remained to be validated. In addition, the major changes after recuration entries in dbPPT [11] and dbPAF [12] were analyzed. From the 560 801 items reserved in EPSD, up to 525 134 (93.64%) p-sites were identical to the previous two databases without any changes (Figure 2E). There were 3661 (0.65%) p-sites with position changes, and 32 006 (5.71%) p-sites underwent changes in UniProt IDs (Figure 2E). Both changes were resulted from the updates of sequences or accession numbers in UniProt [42]. We deleted 4375 p-sites which were mistakenly collected into the two previous databases.

The usage of EPSD

The online service of the EPSD was developed in an easy-to-use manner. As an example, here, we used human PLK1




Figure 2. The data counts of p-sites in the EPSD. (A) A heatmap of the distribution of p-sites, protein entries and pS, pT and pY residues, for each species in the EPSD. More details are shown in [Supplementary Table S4](#). (B) The distribution of numbers of p-sites in protein substrates. (C) The disorder propensity scores were calculated by IUPred [62] for p-sites in eight species. (D) The distribution of numbers of human p-sites in different cells or tissues. (E) The major changes after rechecking entries in dbPPT [11] and dbPAF [12], including identical, position changed (Pos. changed), UniProt ID changed and deleted p-sites.

protein (UniProt ID: P53350), an important serine/threonine kinase that plays important roles in mitosis [63], autophagy and cell death pathways [13], to describe the usage of the EPSD. From the home or search page (<http://epsd.biocuckoo.cn/Search.php>), by using the option of ‘Substrate Search’, users can select the ‘Protein Name’ and input ‘Serine/threonine-protein kinase PLK1’ to query the database (Figure 3A). The results will be shown in a tabular format with information for the EPSD ID, UniProt accession, gene name, protein name and species (Figure 3A). By clicking on ‘EP0017523’, the detailed information for human PLK1 can be viewed. In the EPSD, we mapped all integrated phosphoproteins to PDB [64] and found 5774 proteins containing at least one 3D structure. For proteins such as human PLK1, a representative 3D structure was visualized by 3Dmol.js (<http://3dmol.csb.pitt.edu/>) [65] (Figure 3B). All p-sites or a specific p-site can be selected for visualization in the PLK1 structure (Figure 3B).

Since previous studies demonstrated that p-sites located in protein disordered regions evolve rapidly and are likely to result in nonfunctional phosphorylation events [52, 66], the EPSD used the program package of IUPred (<https://iupred.elte.hu/>) [62], a tool for the prediction of disordered protein regions, to calculate the disorder propensity score for each residue of the phosphoproteins in the eight organisms. Such information will be helpful for biologists to prioritize potentially functional p-sites. For convenience, all p-sites of PLK1 were summarized in a schematic diagram of the protein sequence together with the calculated disorder propensity score for each residue, while the details of p-sites are shown in a tabular list (Figure 3C). For each known

p-site, the position, phosphopeptide centered on the pS/pT/pY residues flanked by seven residues upstream and seven residues downstream, and references are provided (Figure 3C). By clicking on the ‘References’ of a known p-site, details regarding the original phosphopeptides, peptide IDs, classes, LP scores, cell/tissue samples or integrated sources and PMIDs of references can be viewed (Figure 3C).

More annotations of human PLK1 can be accessed by clicking on either the ‘Integrated Annotations’ button (Figure 3B) or the ‘Annotation’ option in the left column to reveal the annotation summary (Figure 3D). By clicking on the button ‘PhosphoSitePlus’ in the annotation list (Figure 3D), protein kinases that phosphorylate PLK1 curated in PhosphoSitePlus [6, 7] can be viewed (Figure 3E). The details of the integrative annotations for human PLK1 are shown in Figure 4. The PLK1 T210 residue is a critical p-site, which can be phosphorylated by Aurora kinase A (AurA), and its phosphorylation level positively correlates with the kinase activity [13]. Phospho.ELM only curated one regulatory kinase LOK of T210 [4, 5], whereas RegPhos [56] annotated T210 modified by AurA and LOK. Also, PSEA collected three kinases, including AurA, Cot and LOK for modifying T210 [53]. PhosphoSitePlus [6, 7] curated four kinases with an additional one as Aurora kinase B (AurB), which was reported to phosphorylate T210 during mitosis [67] (Figure 4). In regard to genetic variation and mutation, we found that cancer mutations annotated in The Cancer Genome Atlas (TCGA) [68] can alter two p-sites including S326 and Y582 in PLK1, while the functional consequences of these changes remain to be studied




Figure 3. The ‘Substrate Search’ option of the EPSPD. (A) One or multiple keywords such as ‘Serine/threonine-protein kinase PLK1’ can be inputted, and the results will be returned in a tabular format. (B) The protein entry of human PLK1. (C) The p-sites of PLK1 are shown in a schematic diagram of the protein sequence and in a tabular list. (D) The annotation summary of PLK1. (E) Protein kinases annotated in PhosphoSitePlus [6, 7] that phosphorylate PLK1.

(Figure 4). For functional annotations, PLK1 was annotated as an autophagy and cell death regulator in our recently developed database THANATOS (40). There were 19 protein 3D structures of PLK1 maintained in PDB [64], and its molecular weight and Isoelectric point were calculated as 68 123.59 Da and 9.09, respectively (Figure 4). The functional domains in PLK1 were annotated. The phosphorylation level of PLK1 T210 is significantly up-regulated in pediatric acute lymphoblastic leukemia, and such a PTM-disease association (PDA) was curated in PTMD [69] (Figure 4). Moreover, 2940 interacting partners and 200 records of drug-target relations, as well as the orthologous information of PLK1, are present (Figure 4). PPIs were integrated from seven public databases, including STRING [70], IID [71], inBio Map™ [72], Mentha [73], HINT [74], iRefIndex [75] and PINA [76]. For each resource, we counted the number of PPIs (Supplementary Figure S1A) and interacting proteins (Supplementary Figure S1B) in *H. sapiens*. It was found that only 8885 PPIs (0.18%) and 8545 proteins (27.01%) were annotated by all databases. We also counted the number of interacting partners of human PLK1 and found only 28 proteins covered by all seven databases (Supplementary Figure S2C). From the Therapeutic Target Database [77], human PLK1 was annotated as a clinical trial target for a number of agents such as Rigosertib, BI2536 and Volasertib (Figure 4). In particular, Volasertib has been approved by the Food and Drug Administration as the breakthrough therapy for the treatment of acute myeloid leukemia patients [16]. A number of biological pathways that involve PLK1 are also shown (Figure 4), and PLK1 is activated by E2F Transcription Factor 1 (E2F1) annotated by TRRUST [78]. From

the TCGA [68], International Cancer Genome Consortium (ICGC) [79], BioXpress [80] and analogous databases, 36 476 records of mRNA expression in 48 cancer types were integrated for PLK1, which is significantly overexpressed in breast cancer (Figure 4). Meanwhile, EPSPD integrated the protein expression levels of PLK1 measured in 47 tissues, which recorded that PLK1 is highly expressed in testis (Figure 4). As a multilocalized protein, human PLK1 can locate at a variety of subcellular compartments, such as centrosome, kinetochore and midbody (Figure 4).

For convenience, we further implemented four additional options to search the database, including peptide search, advanced search, batch search and BLAST search (Supplementary Figure S2). The first option allows users to submit a phosphopeptide such as ‘KKpTLCGTPNYIAPEVLSK’ in which a small ‘p’ was put in front of an S/T/Y residue to denote a p-site (Supplementary Figure S2A), while the second option permits multiple terms to be inputted for querying the database (Supplementary Figure S2B). Multiple gene names or accession numbers in a line-by-line format can be inputted in the batch search option (Supplementary Figure S2C), whereas one protein sequence in FASTA format can be submitted for searching identical or homologous proteins in the BLAST search option (Supplementary Figure S2D). In addition, phosphoproteins in the EPSPD can be browsed by species (Supplementary Figure S2E).

Discussion

Protein phosphorylation is one of the most ubiquitous and well-studied PTMs, and recent advances in large-scale phosphopro-




Figure 4. The overview of the 15 types of annotations for human PLK1 integrated into the EPSD. A brief summary of all the data resources used in this study is shown in Supplementary Table S2. The details regarding the processing of each resource are shown in the Supplementary methods.

teomics have generated a vast amount of large p-site data in eukaryotes [1–8, 10–12]. Undoubtedly, the collection, biocuration, integration and annotation of experimentally characterized p-sites will provide highly useful resources for better understanding the molecular mechanisms and biological functions of eukaryotic phosphorylation. Although a dozen phosphorylation databases have been established, two issues require attention. First, the continuous update of the databases through literature curation is important for providing a more integrative data set of the known p-sites. For example, although dbPPT [11] and dbPAF [12] already contain 565 176 known p-sites, the update of the EPSD still expanded the number to 1 616 804, with a 2.86-fold increase. Second, multidimensional annotations of p-sites from various types of public resources will greatly enhance the usefulness of the databases. In fact, a number of phosphorylation databases have included other types of annotations. For example, dbPTM integrated PDAs and PTM crosstalk events in its 2019 update [9], whereas the PhosphoSitePlus 2014 update provided at least three highly quality annotation files, including ‘Kinase Substrate’ for manually curated kinase-substrate relations, ‘PTMVar’ for missense mutations occurring at or around p-sites and ‘Regulatory sites’ for functional p-sites [6]. In the EPSD, we integrated 15 types of annotations from 100 public resources for eight model organisms. Compared with dbPPT and dbPAF (~0.35 GB), the EPSD has a total data size of 14.1 GB, which represents a 40-fold increase in data volume (Supplementary Table S5).

Besides providing comprehensive annotations for individual phosphoproteins and p-sites, the data in EPSD could also be used for other purposes, e.g. cancer systems biology studies in the network or pathway level. Recently, cancer genome sequencing provided a great opportunity in profiling the molecular landscapes of human tumors, while the modeling of cancer-associated signaling networks was helpful for analyzing the cancer evolutionary dynamics, detecting early-warning signals, probing tumor heterogeneity and prioritizing potential agents to overcome drug resistance [81, 82]. How human signaling networks are rewired by cancer mutations remained to be dissected [83, 84]. Here, we focused on the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway, one of the most aberrantly activated pathways in driving cancer progression [81, 84, 85], and related annotations were directly retrieved from EPSD. We re-illustrated the simplified pathway and observed that all the 21 major components are phosphorylated, with at least three known p-sites changed by cancer mutations integrated from TCGA [68], ICGC [79] and COSMIC [86] (Supplementary Figure S3). In the pathway, class I PI3Ks phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP₂) into phosphatidylinositol-3,4,5-trisphosphate (PIP₃) for promoting the activation of downstream signaling, whereas PTEN acts as a tumor suppressor and inhibits the pathway activation through dephosphorylating PIP₃ to PIP₂ [87] (Supplementary Figure S3). The enzyme activities of both PI3Ks and PTEN are regulated

by phosphorylation [87, 88]. PIK3CB, a member of class I PI3Ks, is autophosphorylated at S1070 that inhibits its lipid kinase activity [88]. From EPSD, we found a missense mutation S1070Y from ICGC colon adenocarcinoma, and such a mutation will enhance the lipid kinase activity of PIK3CB to produce more PIP₃ molecules, which might up-regulate the PI3K/AKT/mTOR pathway. Although it was well documented that the C-terminal phosphorylation of PTEN plays a critical role in regulating its phosphatase activity [87], EPSD contained an HTP p-site at S170, and a mutation of S170 N was demonstrated to significantly disrupt its activity [89]. In EPSD, the S170 N mutation could be found in multiple cancer types and might contribute to activate the PI3K/AKT/mTOR pathway through the accumulation of PIP₃. Further studies need to be conducted to exploit whether other cancer mutations that change p-sites are also involved in the dysregulated activation of the PI3K/AKT/mTOR pathway.

For the future, we will continuously maintain and update the EPSD database, when newly identified p-sites are reported in the literature. More species will be added with experimentally identified p-sites. Additionally, we will include more annotations from other public resources to provide a more comprehensive resource for eukaryotic phosphorylation.

Key Points

- We reviewed the mainstream databases for the collection and annotation of protein p-sites in eukaryotes.
- We developed an integrative resource named EPSD which contained 1 616 804 known p-sites in 209 326 proteins from 68 eukaryotic species, by both literature curation and database integration.
- We provided rich annotations for phosphoproteins and p-sites of eight model organisms by integrating the knowledge from 100 additional resources that covered 15 aspects.

Supplementary Data

Supplementary data are available online at <https://academic.oup.com/bib>.

Acknowledgement

The authors thank Drs Wankun Deng, Haodong Xu and Ying Zhang for their helpful comments during the database construction. American Journal Experts reviewed the manuscript prior to submission.

Funding

Funding for open access charge: Special Project on Precision Medicine under the National Key R&D Program (2017YFC0906600, 2018YFC0910500), the Natural Science Foundation of China (31930021, 31970633, 31671360, 81701567), the Fundamental Research Funds for the Central Universities (2017KFXKJC001, 2019kfyRCPY043), Changjiang Scholars Program of China, and the program for HUST Academic Frontier Youth Team.

References

1. Humphrey SJ, Azimifar SB, Mann M. High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics. *Nat Biotechnol* 2015;**33**:990–5.
2. Liu JJ, Sharma K, Zangrandi L, et al. In vivo brain GPCR signaling elucidated by phosphoproteomics. *Science* 2018;**360**.
3. Blom N, Kreegipuu A, Brunak S. PhosphoBase: a database of phosphorylation sites. *Nucleic Acids Res* 1998;**26**:382–6.
4. Diella F, Cameron S, Gemund C, et al. Phospho.ELM: a database of experimentally verified phosphorylation sites in eukaryotic proteins. *BMC Bioinformatics* 2004;**5**:79.
5. Dinkel H, Chica C, Via A, et al. Phospho.ELM: a database of phosphorylation sites—update 2011. *Nucleic Acids Res* 2011;**39**:D261–7.
6. Hornbeck PV, Zhang B, Murray B, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. *Nucleic Acids Res* 2015;**43**:D512–20.
7. Hornbeck PV, Chabra I, Kornhauser JM, et al. PhosphoSite: a bioinformatics resource dedicated to physiological protein phosphorylation. *Proteomics* 2004;**4**:1551–61.
8. Lee TY, Huang HD, Hung JH, et al. dbPTM: an information repository of protein post-translational modification. *Nucleic Acids Res* 2006;**34**:D622–7.
9. Huang KY, Lee TY, Kao HJ, et al. dbPTM in 2019: exploring disease association and cross-talk of post-translational modifications. *Nucleic Acids Res* 2019;**47**:D298–d308.
10. Huang H, Arighi CN, Ross KE, et al. iPTMnet: an integrated resource for protein post-translational modification network discovery. *Nucleic Acids Res* 2018;**46**:D542–d550.
11. Cheng H, Deng W, Wang Y, et al. dbPPT: a comprehensive database of protein phosphorylation in plants. *Database (Oxford)* 2014;**2014**:bau121.
12. Ullah S, Lin S, Xu Y, et al. dbPAF: an integrative database of protein phosphorylation in animals and fungi. *Sci Rep* 2016;**6**:23534.
13. Chen LL, Wang YB, Song JX, et al. Phosphoproteome-based kinase activity profiling reveals the critical role of MAP2K2 and PLK1 in neuronal autophagy. *Autophagy* 2017;**13**:1969–80.
14. Humphrey SJ, James DE, Mann M. Protein phosphorylation: a major switch mechanism for metabolic regulation. *Trends Endocrinol Metab* 2015;**26**:676–87.
15. Wagih O, Reimand J, Bader GDMIMP. Predicting the impact of mutations on kinase-substrate phosphorylation. *Nat Methods* 2015;**12**:531–3.
16. Van den Bossche J, Lardon F, Deschoolmeester V, et al. Spotlight on volasertib: preclinical and clinical evaluation of a promising Plk1 inhibitor. *Med Res Rev* 2016;**36**:749–86.
17. Drake JM, Paull EO, Graham NA, et al. Phosphoproteome integration reveals patient-specific networks in prostate cancer. *Cell* 2016;**166**:1041–54.
18. Kreegipuu A, Blom N, Brunak S. PhosphoBase, a database of phosphorylation sites: release 2.0. *Nucleic Acids Res* 1999;**27**:237–9.
19. Zanzoni A, Ausiello G, Via A, et al. Phospho3D: a database of three-dimensional structures of protein phosphorylation sites. *Nucleic Acids Res* 2007;**35**:D229–31.
20. Zanzoni A, Carbajo D, Diella F, et al. Phospho3D 2.0: an enhanced database of three-dimensional structures of phosphorylation sites. *Nucleic Acids Res* 2011;**39**:D268–71.
21. Yang CY, Chang CH, Yu YL, et al. PhosphoPOINT: a comprehensive human kinase interactome and phospho-protein database. *Bioinformatics* 2008;**24**:i14–20.

22. Li H, Xing X, Ding G, et al. SysPTM: a systematic resource for proteomic research on post-translational modifications. *Mol Cell Proteomics* 2009;**8**:1839–49.
23. Li J, Jia J, Li H, et al. SysPTM 2.0: an updated systematic resource for post-translational modification. *Database (Oxford)* 2014;**2014**:bau025.
24. Safaei J, Manuch J, Gupta A, et al. Prediction of 492 human protein kinase substrate specificities. *Proteome Sci* 2011;**9**(Suppl 1):S6.
25. Ross KE, Huang H, Ren J, et al. iPTMnet: integrative bioinformatics for studying PTM networks. *Methods Mol Biol* 2017;**1558**:333–53.
26. Olsen JV, Blagoev B, Gnäd F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. *Cell* 2006;**127**:635–48.
27. Gnäd F, Gunawardena J, Mann M. PHOSIDA 2011: the posttranslational modification database. *Nucleic Acids Res* 2011;**39**:D253–60.
28. Bodenmiller B, Malmstrom J, Gerrits B, et al. PhosphoPep—a phosphoproteome resource for systems biology research in *Drosophila* Kc167 cells. *Mol Syst Biol* 2007;**3**:139.
29. Bodenmiller B, Aebersold R. Phosphoproteome resource for systems biology research. *Methods Mol Biol* 2011;**694**:307–22.
30. Ovelheiro D, Carrascal M, Casas V, et al. LymPHOS: design of a phosphosite database of primary human T cells. *Proteomics* 2009;**9**:3741–51.
31. Nguyen TD, Vidal-Cortes O, Gallardo O, et al. LymPHOS 2.0: an update of a phosphosite database of primary human T cells. *Database (Oxford)* 2015;**2015**.
32. Gribskov M, Fana F, Harper J, et al. PlantsP: a functional genomics database for plant phosphorylation. *Nucleic Acids Res* 2001;**29**:111–3.
33. Nuhse TS, Stensballe A, Jensen ON, et al. Phosphoproteomics of the Arabidopsis plasma membrane and a new phosphorylation site database. *Plant Cell* 2004;**16**:2394–405.
34. Heazlewood JL, Durek P, Hummel J, et al. PhosPhAt: a database of phosphorylation sites in Arabidopsis thaliana and a plant-specific phosphorylation site predictor. *Nucleic Acids Res* 2008;**36**:D1015–21.
35. Durek P, Schmidt R, Heazlewood JL, et al. PhosPhAt: the Arabidopsis thaliana phosphorylation site database. An update. *Nucleic Acids Res* 2010;**38**:D828–34.
36. Yao Q, Ge H, Wu S, et al. P(3)DB 3.0: from plant phosphorylation sites to protein networks. *Nucleic Acids Res* 2014;**42**:D1206–13.
37. Gao J, Agrawal GK, Thelen JJ, et al. P3DB: a plant protein phosphorylation database. *Nucleic Acids Res* 2009;**37**:D960–2.
38. Grimsrud PA, den Os D, Wenger CD, et al. Large-scale phosphoprotein analysis in Medicago truncatula roots provides insight into in vivo kinase activity in legumes. *Plant Physiol* 2010;**152**:19–28.
39. Rose CM, Venkateshwaran M, Grimsrud PA, et al. Medicago phosphoprotein database: a repository for Medicago truncatula phosphoprotein data. *Front Plant Sci* 2012;**3**:122.
40. Bai Y, Chen B, Li M, et al. FPD: a comprehensive phosphorylation database in fungi. *Fungal Biol* 2017;**121**:869–75.
41. Beltrao P, Albanese V, Kenner LR, et al. Systematic functional prioritization of protein posttranslational modifications. *Cell* 2012;**150**:413–25.
42. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* 2019;**47**:D506–d515.
43. Keshava Prasad TS, Goel R, Kandasamy K, et al. Human protein reference database—2009 update. *Nucleic Acids Res* 2009;**37**:D767–72.
44. Stark C, Su TC, Breitskreutz A, et al. PhosphoGRID: a database of experimentally verified in vivo protein phosphorylation sites from the budding yeast *Saccharomyces cerevisiae*. *Database (Oxford)* 2010;**2010**:bap026.
45. Oughtred R, Stark C, Breitskreutz BJ, et al. The BioGRID interaction database: 2019 update. *Nucleic Acids Res* 2019;**47**:D529–d541.
46. Humphrey SJ, Yang G, Yang P, et al. Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2. *Cell Metab* 2013;**17**:1009–20.
47. Xue Y, Ren J, Gao X, et al. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. *Mol Cell Proteomics* 2008;**7**:1598–608.
48. Linding R, Jensen LJ, Ostheimer GJ, et al. Systematic discovery of in vivo phosphorylation networks. *Cell* 2007;**129**:1415–26.
49. Song C, Ye M, Liu Z, et al. Systematic analysis of protein phosphorylation networks from phosphoproteomic data. *Mol Cell Proteomics* 2012;**11**:1070–83.
50. Wang Y, Cheng H, Pan Z, et al. Reconfiguring phosphorylation signaling by genetic polymorphisms affects cancer susceptibility. *J Mol Cell Biol* 2015;**7**:187–202.
51. Li L, Tibiche C, Fu C, et al. The human phosphotyrosine signaling network: evolution and hotspots of hijacking in cancer. *Genome Res* 2012;**22**:1222–30.
52. Studer RA, Rodriguez-Mias RA, Haas KM, et al. Evolution of protein phosphorylation across 18 fungal species. *Science* 2016;**354**:229–32.
53. Jung I, Matsuyama A, Yoshida M, et al. PostMod: sequence based prediction of kinase-specific phosphorylation sites with indirect relationship. *BMC Bioinformatics* 2010;**11**(Suppl 1):S10.
54. Suo SB, Qiu JD, Shi SP, et al. PSEA: kinase-specific prediction and analysis of human phosphorylation substrates. *Sci Rep* 2014;**4**:4524.
55. Hu J, Rho HS, Newman RH, et al. PhosphoNetworks: a database for human phosphorylation networks. *Bioinformatics* 2014;**30**:141–2.
56. Lee TY, Bo-Kai Hsu J, Chang WC, et al. RegPhos: a system to explore the protein kinase-substrate phosphorylation network in humans. *Nucleic Acids Res* 2011;**39**:D777–87.
57. Liberti S, Sacco F, Calderone A, et al. HuPho: the human phosphatase portal. *FEBS J* 2013;**280**:379–87.
58. Duan G, Li X, Kohn M. The human DEP(O)phosphorylation database DEPOD: a 2015 update. *Nucleic Acids Res* 2015;**43**:D531–5.
59. Xue Y, Liu Z, Cao J, et al. GPS 2.1: enhanced prediction of kinase-specific phosphorylation sites with an algorithm of motif length selection. *Protein Eng Des Sel* 2011;**24**:255–60.
60. Zou L, Wang M, Shen Y, et al. PKIS: computational identification of protein kinases for experimentally discovered protein phosphorylation sites. *BMC Bioinformatics* 2013;**14**:247.
61. Patrick R, Le Cao KA, Kobe B, et al. PhosphoPICK: modelling cellular context to map kinase-substrate phosphorylation events. *Bioinformatics* 2015;**31**:382–9.
62. Meszaros B, Erdos G, Dosztanyi Z. IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding. *Nucleic Acids Res* 2018;**46**:W329–w337.
63. Liu Z, Ren J, Cao J, et al. Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes. *Brief Bioinform* 2013;**14**:344–60.
64. Burley SK, Berman HM, Bhikadiya C, et al. RCSB protein data bank: biological macromolecular structures enabling research and education in fundamental biology,

- biomedicine, biotechnology and energy. *Nucleic Acids Res* 2019;**47**:D464–d474.
65. Rego N, Koes D. 3Dmol.js: molecular visualization with WebGL. *Bioinformatics* 2015;**31**:1322–4.
 66. Landry CR, Levy ED, Michnick SW. Weak functional constraints on phosphoproteomes. *Trends Genet* 2009;**25**:193–7.
 67. Carmena M, Pinson X, Platani M, et al. The chromosomal passenger complex activates polo kinase at centromeres. *PLoS Biol* 2012;**10**:e1001250.
 68. Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. *Cell* 2018;**173**:283–5.
 69. Xu H, Wang Y, Lin S, et al. PTMD: a database of human disease-associated post-translational modifications. *Genomics Proteomics Bioinformatics* 2018;**16**:244–51.
 70. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019;**47**:D607–d613.
 71. Kotlyar M, Pastrello C, Malik Z, et al. IID 2018 update: context-specific physical protein-protein interactions in human, model organisms and domesticated species. *Nucleic Acids Res* 2019;**47**:D581–d589.
 72. Li T, Wernersson R, Hansen RB, et al. A scored human protein-protein interaction network to catalyze genomic interpretation. *Nat Methods* 2017;**14**:61–4.
 73. Calderone A, Castagnoli L, Cesareni G. mentha: a resource for browsing integrated protein-interaction networks. *Nat Methods* 2013;**10**:690–1.
 74. Das J, Yu H. HINT: high-quality protein interactomes and their applications in understanding human disease. *BMC Syst Biol* 2012;**6**:92.
 75. Razick S, Magklaras G, Donaldson IM. iRefIndex: a consolidated protein interaction database with provenance. *BMC Bioinformatics* 2008;**9**:405.
 76. Cowley MJ, Pinese M, Kassahn KS, et al. PINA v2.0: mining interactome modules. *Nucleic Acids Res* 2012;**40**:D862–5.
 77. Li YH, Yu CY, Li XX, et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. *Nucleic Acids Res* 2018;**46**:D1121–d1127.
 78. Han H, Cho JW, Lee S, et al. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. *Nucleic Acids Res* 2018;**46**:D380–d386.
 79. Zhang J, Bajari R, Andric D, et al. The international cancer genome consortium data portal. *Nat Biotechnol* 2019;**37**:367–9.
 80. Dingerdissen HM, Torcivia-Rodriguez J, Hu Y, et al. BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery. *Nucleic Acids Res* 2018;**46**:D1128–d1136.
 81. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. *Semin Cancer Biol* 2013;**23**:279–85.
 82. Wang E, Zou J, Zaman N, et al. Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. *Semin Cancer Biol* 2013;**23**:286–92.
 83. Zaman N, Li L, Jaramillo ML, et al. Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. *Cell Rep* 2013;**5**:216–23.
 84. McGee SR, Tibiche C, Trifiro M, et al. Network analysis reveals a signaling regulatory loop in the PIK3CA-mutated breast cancer predicting survival outcome. *Genomics Proteomics Bioinformatics* 2017;**15**:121–9.
 85. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? *Nat Rev Clin Oncol* 2018;**15**:273–91.
 86. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogue of somatic mutations in cancer. *Nucleic Acids Res* 2019;**47**:D941–d947.
 87. Alvarez-Garcia V, Tawil Y, Wise HM, et al. Mechanisms of PTEN loss in cancer: It's all about diversity. *Semin Cancer Biol* 2019;**59**:66–79.
 88. Czupalla C, Culo M, Muller EC, et al. Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma. *J Biol Chem* 2003;**278**:11536–45.
 89. Han SY, Kato H, Kato S, et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. *Cancer Res* 2000;**60**:3147–51.